Mylamba 600 mg. 300 mg TABLET
PDF Leaflet Revision Date: 15 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents from 12 years of age.
Dosage (summary)
One tablet once daily for adults and adolescents; not for those weighing less than 40 kg.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding due to potential HIV transmission.
Key Drug Interactions
- Avoid with other lamivudine or emtricitabine products
- Caution with trimethoprim/sulfamethoxazole
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Severe hepatic impairment
- Severe renal impairment
- Children under 12 years
Common side effects
- Hypersensitivity reactions
- Nausea
- Vomiting
- Diarrhoea
- Rash
Counselling Points
- Monitor for hypersensitivity symptoms
- Do not restart if hypersensitivity occurs
- Regular adherence to therapy is crucial
Serious warnings
- Risk of lactic acidosis
- Severe hypersensitivity reactions
- Potential for mitochondrial dysfunction
Important Disclaimer
The Mylamba 600 mg. 300 mg TABLET professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
